Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 224

Sort by

Sort Order Select

Journal Articles

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Blood (2020) 135 (16): 1396–1405.

https://doi.org/10.1182/blood.2019003526

Published: 2020

Includes: Supplemental data

Journal Articles

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Lynne I. Wagner, PhD, Kathleen Toomey, MD, Sikander Ailawadhi, MD, Sundar Jagannath, Cristina Gasparetto, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, James L. Omel, MD, James W. Hardin, PhD, Hans C. Lee, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Donna Catamero, ANP-BC, OCN, CCRC, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 1843.

https://doi.org/10.1182/blood-2019-126143

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Francesco Saraceni, Myriam Labopin, MD, Edouard Forcade, MD, Nicolaus Kröger, Gerard Socie, MD PhD, Riitta Niittyvuopio, Jan J Cornelissen, MD PhD, Hélène Labussière-Wallet, Didier Blaise, MD PhD, Goda Choi, MD PhD, Jenny Byrne, MD PhD, Gaëlle Guillerm, MD, Thierry Lamy, PhD MD, Jordi Esteve, Ali Bazarbachi, MD PhD, Bipin N. Savani, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 2038.

https://doi.org/10.1182/blood-2019-127713

Published: 2019

Journal Articles

Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML

Ivy Abraham, MD, Garth Rauscher, PhD MPH, Anand Ashwin Patel, MD, Wendy Stock, MD, Maryam Zia, MD, Sushma Bharadwaj, MD, Koosha Paydary, MD, Maria Acevedo-Mendez, John P Galvin, MDMS,MPH, William Pearse, MD, Jessica K. Altman, John G. Quigley, Priya Rajakumar, MD, Melissa L. Larson, MD, Irum Khan, MD

Blood (2019) 134 (Supplement_1): 3413.

https://doi.org/10.1182/blood-2019-124974

Published: 2019

Journal Articles

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

Adam Zayac, MD, Andrew Matthew Evens, DO,MMSc, Andrzej Stadnik, MPH, BS, Stephen D. Smith, MD, Deepa Jagadeesh, MDMPH, Lori A. Leslie, MD, Catherine Wei, MD MA, Seo-Hyun Kim, MD, Seema Naik, MD, Suchitra Sundaram, MD, Nishitha Reddy, MD, Umar Farooq, MD, Vaishalee P. Kenkre, MD, Narendranath Epperla, MDMS, Kristie A. Blum, MD, Nadia Khan, MD, Daulath Singh, MD, Juan Pablo Alderuccio, MD, Amandeep Godara, MD, Maryam Yazdy, MD, Catherine Diefenbach, MD, Emma Rabinovich, MD, Gaurav Varma, MDMPH, Reem Karmali, MD, Yusra Shao, MD, Asaad Trabolsi, MD, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Sarah Stettner, Ayushi Chauhan, MBBS, Yun Kyong Choi, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Michael C. Churnetski, Kirsten M Boughan, DO, Stephanie Berg, DO, Brad M. Haverkos, MDMPH,MS, Victor M. Orellana-Noia, MD, Christopher D'Angelo, MD, David A. Bond, MD, Seth M Maliske, MD, Ryan Vaca, MD, Gabriela Magarelli, APN, Amy Sperling, BS, Max J. Gordon, MD, Kevin A. David, MD, Paolo Caimi, MD, Manali Kamdar, MD, Craig A. Portell, MD, Parameswaran Venugopal, MD, Izidore S. Lossos, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 402.

https://doi.org/10.1182/blood-2019-122990

Published: 2019

Journal Articles

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Jacob Appelbaum, MD PhD, Anisha Loeb, BA, Kelda Gardner, PA-C, Carole M. Shaw, BA, Paul C. Hendrie, MD PhD, Colin D. Godwin, MDMPhil, Mary-Elizabeth M. Percival, MD, Anna B. Halpern, MD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Michael C. Jensen, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 260.

https://doi.org/10.1182/blood-2019-131678

Published: 2019

Journal Articles

Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)

Blood (2019) 134 (Supplement_1): 69.

https://doi.org/10.1182/blood-2019-129499

Published: 2019

Journal Articles

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Anas Younes, MD, Grzegorz Nowakowski, MD, Allison C. Rosenthal, DO, Lori A. Leslie, MD, Han W. Tun, MD, Matthew A. Lunning, DO, FACP, Iris Isufi, MD, Robert Martell, MD PhD, Krish Patel, MD

Blood (2019) 134 (Supplement_1): 5327.

https://doi.org/10.1182/blood-2019-131851

Published: 2019

Journal Articles

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Anna Guidetti, MD, Giulia Perrone, MD, Paola Coluccia, MD, Luca Fumagalli, MD, Anna Dodero, MD, Lucia Farina, MD, Flavio Arienti, MD, Filippo Bagnoli, MD, Luca Pappalettera, MD, Debora Degli Innocenti, Cristiana Carniti, PhD, Daniela Codazzi, MD, Paolo Corradini

Blood (2019) 134 (Supplement_1): 5619.

https://doi.org/10.1182/blood-2019-125286

Published: 2019

Journal Articles

The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes

Abhay Singh, MBBS, MPH, Sarah Sadek, MD, Mark G. Faber, DO, Jeffrey Baron, PharmD, James E. Thompson, MD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD, Swapna Thota, MD

Blood (2019) 134 (Supplement_1): 5095.

https://doi.org/10.1182/blood-2019-132040

Published: 2019

Journal Articles

Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS

Kelda Gardner, PA-C, Megan Othus, PhD, Carole M. Shaw, BA, Pamela S. Becker, MD PhD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 5093.

https://doi.org/10.1182/blood-2019-130965

Published: 2019

Journal Articles

Retrospective Electronic Medical Records Study of Treatment Patterns Among CLL Patients in the CancerLinQ Research Database

Shaum M Kabadi, PhDMPH, Supriya R Kumar, MS, Jennifer L Wong

Blood (2019) 134 (Supplement_1): 5810.

https://doi.org/10.1182/blood-2019-123014

Published: 2019

Journal Articles

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Daniel R. Richardson, MD MA, David M Swoboda, MD, Anastasia Ivanova, PhD, Steven M Johnson, MD, Jonathan Galeotti, MD MS, Sonia Esparza, MD, Onyee Chan, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Nathan D Montgomery, MD, David A Sallman, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 2598.

https://doi.org/10.1182/blood-2019-122929

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Francesco Saraceni, Myriam Labopin, MD, Riitta Niittyvuopio, Gerard Socie, MD PhD, Nicolaus Kröger, Edouard Forcade, MD, Paul V Browne, MB,FRCPath, Péter Reményi, Jan J Cornelissen, MD PhD, Stephen Robinson, MBBS, PhD BSc, Ibrahim Yakoub-Agha, MD PhD, Thierry Lamy, PhD MD, Eolia Brissot, MD PhD, Bipin N. Savani, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 3327.

https://doi.org/10.1182/blood-2019-127810

Published: 2019

Journal Articles

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari, MD, Dorothy Romanus, RPh, PhD, Aditya Raju, Lauren Cain, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 1827.

https://doi.org/10.1182/blood-2019-121658

Published: 2019

Journal Articles

Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?

Maryam Sarraf Yazdy, Anthony R. Mato, Bruce D. Cheson

Blood (2019) 133 (2): 121–129.

https://doi.org/10.1182/blood-2018-08-869503

Published: 2019

Journal Articles

Geriatric Assessment (GA) Measures and Patient-Reported Outcomes (PROs) Among Older Adults Treated in a Phase 1b Study for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Heidi D. Klepin, MD MS, Avrita Campinha-Bacote, Wan-Jen Hong, Patrick Phuong, Jue Wang, Mehrdad Mobasher, MD MPH, Peter Trask

Blood (2018) 132 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2018-99-116038

Published: 2018

Journal Articles

Association of Clinical Epidemiologic Exposures and Overall Survival with Genome-Wide DNA Methylation Profiles in Acute Myeloid Leukemia: Analysis of the Mayo Clinic AML Epidemiology Cohort

César J. Torres-Gutierrez, BS, Michael G. Heckman, Ryan A. Hlady, Rhett P. Ketterling, Lisa Z. Sproat, Kathryn E. Pearce, Elizabeth R. Lesser, Nancy N. Diehl, Laura E. Finn, Liuyan Jennifer Jiang, Keith D. Robertson, James R. Cerhan, MD PhD, James M. Foran, MD

Blood (2018) 132 (Supplement 1): 3987.

https://doi.org/10.1182/blood-2018-99-119386

Published: 2018

Journal Articles

Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia

Sarah Elsayed, MD, Barry E. Storer, PhD, Bruno C. Medeiros, MD, Mona Ahmed Asslan, MSc, Ylinne Lynch, MD, Jennifer E. Nyland, PhD, Pamela S. Becker, MD, Mary-Elizabeth M. Percival, MD, Elihu H. Estey, MD, Mohamed L. Sorror, MD MSc

Blood (2018) 132 (Supplement 1): 3992.

https://doi.org/10.1182/blood-2018-99-117415

Published: 2018

Journal Articles

Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real World Data from an Ongoing, National, Multi-Center, Non-Interventional Study

Daniel Lechner, MD, Richard Greil, MD, Bernd Hartmann, Maria-Theresa Krauth, MD, Heinz Gisslinger, Ursula Vogl, Leopold Ohler, Hildegard T. Greinix, MD, Siegfried Sormann, Johannes Andel, Ernst Rechberger, Hermine Agis, MD

Blood (2018) 132 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2018-99-116292

Published: 2018

NARROW

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes

Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS

Retrospective Electronic Medical Records Study of Treatment Patterns Among CLL Patients in the CancerLinQ Research Database

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?

Geriatric Assessment (GA) Measures and Patient-Reported Outcomes (PROs) Among Older Adults Treated in a Phase 1b Study for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Association of Clinical Epidemiologic Exposures and Overall Survival with Genome-Wide DNA Methylation Profiles in Acute Myeloid Leukemia: Analysis of the Mayo Clinic AML Epidemiology Cohort

Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia

Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real World Data from an Ongoing, National, Multi-Center, Non-Interventional Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only